We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > APL-1702

News List

Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira® prnasia
June 22, 2021
Asieris Pharmaceuticals (Asieris) today announced dosing of the first patient in Europe in its multinational, multicenter, Phase III clinical trial (APRICITY) of its photodynamic drug-device combination product APL-1702, Cevira® which is being ...
Asieris Announces First Patient Administration in the Global Phase III Clinical Trial for APL-1702 prnasia
November 13, 2020
Asieris Pharmaceuticals, a China-based biotech company with global aspirations to discover, develop, and commercialize innovative drugs for the treatment of genitourinary tumors and related diseases, announced today that the first patient was enrolled ...
Cervical dysplasia treatment device approved for global Phase III trial europeanpharmaceuticalreview
July 10, 2020
The cervical dysplasia drug-device product, APL-1702 (Cevira®), offers an alternative to surgery and has been approved to start a clinical trial in China and several other countries.